Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, Hubei, China; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, Hubei, China; Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan 430022, China.
Mol Ther. 2024 Nov 6;32(11):3772-3792. doi: 10.1016/j.ymthe.2024.09.019. Epub 2024 Sep 17.
Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a revolutionary approach in the treatment of malignancies. Despite its remarkable successes, this field continues to grapple with challenges such as scalability, safety concerns, limited therapeutic effect, in vivo persistence, and the need for precise control over CAR expression. In the post-pandemic era of COVID-19 vaccine immunization, the application of messenger RNA (mRNA) encapsulated within lipid nanoparticles (LNPs) has recently garnered significant attention as a potential solution to address these challenges. This review delves into the dynamic landscape of mRNA-LNP technology and its potential implications for CAR-engineered immune cell-based immunotherapy.
嵌合抗原受体 T 细胞（CAR-T）疗法在恶性肿瘤的治疗中已经成为一种革命性的方法。尽管取得了显著的成功，但该领域仍在努力应对一些挑战，如可扩展性、安全性问题、有限的治疗效果、体内持久性以及对 CAR 表达的精确控制。在 COVID-19 疫苗免疫的后疫情时代，封装在脂质纳米颗粒（LNPs）中的信使 RNA（mRNA）的应用最近引起了广泛关注，有望成为解决这些挑战的一种潜在方法。本综述深入探讨了 mRNA-LNP 技术的动态领域及其对 CAR 工程免疫细胞为基础的免疫治疗的潜在影响。
